// App-Quantinova.ai

9531 : Treatment-free survival (TFS), a novel outcome applied to immuno-oncology (IO) agents in advanced melanoma (AM).

Researchers

Presenter

  • Meredith M. Regan

Principal Investigators

  • Lillian Werner

  • Ahmad A. Tarhini

  • Sumati Rao

  • Komal Gupte-Singh

  • Corey Ritchings

  • Michael B. Atkins

  • David F. McDermott

Medical Centers

  • Dana-Farber Cancer Institute, Boston, MA

  • Cleveland Clinic Taussig Cancer Institute, Cleveland, OH

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Georgetown University Lombardi Comprehensive Cancer Center, Washington, DC

  • Beth Israel Deaconess Medical Center, Boston, MA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • NCT01844505

  • NCT01927419

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved